Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.

West AM, Anderson JD, Epstein FH, Meyer CH, Wang H, Hagspiel KD, Berr SS, Harthun NL, Weltman AL, Dimaria JM, Hunter JR, Christopher JM, Kramer CM.

J Am Coll Cardiol. 2011 Aug 30;58(10):1068-76. doi: 10.1016/j.jacc.2011.04.034.

2.

Percutaneous intervention in peripheral artery disease improves calf muscle phosphocreatine recovery kinetics: a pilot study.

West AM, Anderson JD, Epstein FH, Meyer CH, Hagspiel KD, Berr SS, Harthun NL, Weltman AL, Annex BH, Kramer CM.

Vasc Med. 2012 Feb;17(1):3-9. doi: 10.1177/1358863X11431837.

3.

Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism.

Anderson JD, Epstein FH, Meyer CH, Hagspiel KD, Wang H, Berr SS, Harthun NL, Weltman A, Dimaria JM, West AM, Kramer CM.

J Am Coll Cardiol. 2009 Aug 11;54(7):628-35. doi: 10.1016/j.jacc.2009.01.080.

4.

The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.

West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD, Berr SS, Harthun NL, DiMaria JM, Hunter JR, Christopher JM, Chew JD, Winberry GB, Kramer CM.

Atherosclerosis. 2011 Sep;218(1):156-62. doi: 10.1016/j.atherosclerosis.2011.04.005.

5.

Arterial spin labeling MR imaging reproducibly measures peak-exercise calf muscle perfusion: a study in patients with peripheral arterial disease and healthy volunteers.

Pollak AW, Meyer CH, Epstein FH, Jiji RS, Hunter JR, Dimaria JM, Christopher JM, Kramer CM.

JACC Cardiovasc Imaging. 2012 Dec;5(12):1224-30. doi: 10.1016/j.jcmg.2012.03.022.

6.

High-energy phosphate metabolism during incremental calf exercise in patients with unilaterally symptomatic peripheral arterial disease measured by phosphor 31 magnetic resonance spectroscopy.

Greiner A, Esterhammer R, Messner H, Biebl M, Mühlthaler H, Fraedrich G, Jaschke WR, Schocke MF.

J Vasc Surg. 2006 May;43(5):978-86.

7.

Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells.

Pesaro AE, Serrano CV Jr, Katz M, Marti L, Fernandes JL, Parra PR, Campos AH.

J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):447-52. doi: 10.1177/1074248413489771.

PMID:
23739650
8.

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.

Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM.

Am Heart J. 2014 Aug;168(2):205-12.e1. doi: 10.1016/j.ahj.2014.05.004.

9.

The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers.

Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A.

Eur J Clin Pharmacol. 2007 Feb;63(2):113-21.

PMID:
17200833
11.

Co-administration of ezetimibe and simvastatin in acute myocardial infarction.

Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS.

Eur J Clin Invest. 2007 May;37(5):357-63.

PMID:
17461981
12.

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.

Jimenez JG, Rosen JB, Pirags V, Massaad R, Hanson ME, Brudi P, Triscari J.

Diabetes Obes Metab. 2013 Jun;15(6):513-22. doi: 10.1111/dom.12059.

PMID:
23279632
13.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators..

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489.

14.

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.

Rosen JB, Jimenez JG, Pirags V, Vides H, Massaad R, Hanson ME, Brudi P, Triscari J.

Lipids Health Dis. 2013 Jul 16;12:103. doi: 10.1186/1476-511X-12-103.

15.

Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.

Ciriacks K, Coly G, Krishnaswami S, Patel SB, Kidambi S.

Metab Syndr Relat Disord. 2015 Mar;13(2):84-90. doi: 10.1089/met.2014.0114.

PMID:
25490061
16.

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.

Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K.

J Clin Lipidol. 2014 Jan-Feb;8(1):107-16. doi: 10.1016/j.jacl.2013.09.009.

PMID:
24528691
17.

Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.

Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, Shah S.

Diabetes Obes Metab. 2005 Jan;7(1):88-97.

PMID:
15642080
18.
19.

Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.

Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, Gensini GF.

Lipids Health Dis. 2010 Jul 27;9:80. doi: 10.1186/1476-511X-9-80.

20.

Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.

Toth PP, Ballantyne CM, Davidson MH, Tomassini JE, Ramey DR, Neff D, Tershakovec AM, Hu XH, Tunceli K.

J Clin Lipidol. 2012 Mar-Apr;6(2):180-91. doi: 10.1016/j.jacl.2011.11.007.

PMID:
22385552
Items per page

Supplemental Content

Support Center